|
|
|
Volumn 2, Issue 1, 2000, Pages 10-
|
|
Non-small-cell lung cancer Have we reached a "Chemotherapy Efficacy Plateau"?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BIOLOGICAL PRODUCT;
CANCER VACCINE;
CARBOPLATIN;
CETUXIMAB;
CISPLATIN;
CYTOTOXIC AGENT;
DOCETAXEL;
EPIDERMAL GROWTH FACTOR RECEPTOR;
GEFITINIB;
GROWTH FACTOR RECEPTOR;
NAVELBINE;
PACLITAXEL;
PROTEIN P185;
PROTEIN TYROSINE KINASE INHIBITOR;
TAXANE DERIVATIVE;
TRASTUZUMAB;
ADVANCED CANCER;
ANTINEOPLASTIC ACTIVITY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER GROWTH;
CANCER STAGING;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG POTENTIATION;
DRUG TOLERABILITY;
EDITORIAL;
GENE OVEREXPRESSION;
GENOME;
HUMAN;
LUNG NON SMALL CELL CANCER;
ONCOGENE C ERB;
ONCOGENE NEU;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL;
SIDE EFFECT;
SIGNAL TRANSDUCTION;
|
|
EID: 0034463773
PISSN: 15257304
EISSN: None
Source Type: Journal
DOI: None Document Type: Editorial |
|
Times cited : (3)
|
|
References (0)
|
